VivoSeq
Other

Hematological Diseases

0

Pipeline Programs↗

6

Active Trials↗

1

Companies Involved↗

Hematological Diseases is an early-stage landscape with 0 programs across 1 company. The most active players are Shanghai IASO Biotechnology Co., Ltd.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Shanghai IASO Biotechnology Co., Ltd

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

12

clinical trials

Completed6 · 50%
Not yet recruiting3 · 25%
Recruiting3 · 25%

Clinical Trials

Trial Activity

12 trials

UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases
Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 1·NCT07441525·27 enrolled
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Recruiting·MMasonic Cancer Center, University of Minnesota·N/A·NCT01962636·200 enrolled
Longitudinal Studies of Patients and Families With Familial Platelet Disorders With Associated Myeloid Malignancy (FPDMM) Caused by RUNX1 Germline Variants or FPDMM-Like Conditions
Recruiting·NNational Human Genome Research Institute (NHGRI)·N/A·NCT03854318·1,000 enrolled
A Real World Study of Polyene Phosphatidylcholine Injection for the Prevention and Treatment of DILI in Patients With Malignant Hematological Diseases
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·N/A·NCT07476885·1,000 enrolled
IASO-782 in Autoimmune Hematological Diseases
Not yet recruiting·SShanghai IASO Biotechnology Co., Ltd·Phase 1·NCT06534021·16 enrolled
BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.
Not yet recruiting·AAnne Louise Tølbøll Sørensen·Phase 4·NCT07474961·400 enrolled
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases
Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00309842·213 enrolled
Allo HSCT Using RIC for Hematological Diseases
Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT02661035·156 enrolled
Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases
Completed·WWake Forest University Health Sciences·Phase 2·NCT02248597·27 enrolled
Micafungin Versus Intravenous Itraconazole as Empirical Antifungal Therapy for Febrile Neutropenic Patients With Hematological Diseases
Completed·YYonsei University·Phase 2·NCT01344681·153 enrolled
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT02722668·15 enrolled
Pilot Study: Secure Outsourcing of Carfilzomib in the Treatment of Multiple Myeloma to the Hospital at Home (HAH) Setting. Care Organisation Model for New Short Intravenous Infusion Chemotherapies
Completed·UUniversity Hospital, Limoges·N/A·NCT05041933·17 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)